(NASDAQ: TPST) Tempest Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.81%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 64.19%.
Tempest Therapeutics's earnings in 2026 is -$40,472,000.On average, 3 Wall Street analysts forecast TPST's earnings for 2026 to be -$21,840,659, with the lowest TPST earnings forecast at -$20,984,163, and the highest TPST earnings forecast at -$22,483,031. On average, 3 Wall Street analysts forecast TPST's earnings for 2027 to be -$19,721,789, with the lowest TPST earnings forecast at -$18,948,386, and the highest TPST earnings forecast at -$20,301,842.
In 2028, TPST is forecast to generate -$14,506,109 in earnings, with the lowest earnings forecast at -$13,937,242 and the highest earnings forecast at -$14,932,760.